Latest news and press releases about Ardelyx, Inc. (ARDX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor.
Price
| Price | $3.39 |
| Market Cap | $837M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.34 |
| EV / EBITDA | -43.87 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -36.00% |
| Return on Invested Capital | -7.96% |
| Return on Assets | -9.67% |
| Gross Margin | 93.96% |
| Operating Margin | -7.86% |
| Net Margin | -12.35% |
Related companies: BCRX · MAZE · NTLA · PHVS · STOK · SYRE · TRVI
Explore sector: Healthcare · Biotechnology
More sections of ARDX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks